A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease
Phase of Trial: Phase III
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 18 Jan 2019 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 This trial was completed in Czech Republic (end date: 2018-11-09), according to European Clinical Trials Database
- 24 Nov 2018 This trial was completed in Spain (end date: 2018-11-09), according to European Clinical Trials Database.